Document:

EX-10.63

 Exhibit 10.63 

AMENDMENT NO. 2 TO 

AMENDED AND RESTATED LICENSE AGREEMENT 

This Amendment No. 2 to the Amended and Restated License Agreement (this “Amendment”) is made as of October 25,
2017 by and between Histogen, Inc. (“Histogen”) and Allergan Sales, LLC (“Allergan”). 
 WHEREAS,
Suneva Medical, Inc. (“Suneva”) and Histogen previously entered into that certain License Agreement dated as of February 3, 2012 (the “Original Agreement”); 

WHEREAS, on December 16, 2013, Suneva and Histogen entered into the Amended and Restated License Agreement (as modified by
Amendment No. 1 (as defined below), the “License Agreement”; capitalized terms used herein and not otherwise defined shall have the meanings ascribed to such terms in the License Agreement), amending and restating the Original
Agreement in its entirety, maintaining except as otherwise expressly stated therein, the original February 3, 2012 effective date; 

WHEREAS, pursuant to the License Agreement, among other things, Histogen granted to Suneva an exclusive, royalty-bearing license to the
Licensed Intellectual Property, ReGenica Products, and certain future products to be developed in the Field of Use and in the Territory, subject to the terms and conditions of the License Agreement; 

WHEREAS, on July 7, 2017, Allergan and Suneva entered into an Asset Purchase Agreement (the “APA”), pursuant to
which, among other things, Suneva agreed to sell Suneva’s ReGenica product line to Allergan, subject to the terms and conditions set forth in the APA (the “Regenica Transaction”); 

WHEREAS, on July 11, 2017, Suneva, Histogen and Allergan Sales, LLC entered into that certain letter agreement (“Amendment
No. 1”), pursuant to which, among other things, (i) Histogen consented to the assignment by Suneva of the License Agreement to Allergan, (ii) Allergan accepted the assignment of all of Suneva’s rights and
obligations under the License Agreement from and after the closing of the Regenica Transaction (the “Closing”), (iii) Allergan, Suneva and Histogen agreed that with effect from the Closing, Allergan would replace Suneva as a party
to the License Agreement, entitled to all rights granted to Suneva pursuant to the License Agreement and subject to all obligations of Suneva pursuant to the License Agreement and that all references to “Suneva” in the License Agreement
should be deemed references to “Allergan”, and (iv) Allergan, Suneva and Histogen agreed to certain other modifications to the License Agreement to become effective subject to the Closing; and 

WHEREAS, the Closing occurred on July 24, 2017. 

  
 -1- 

 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of
which are hereby acknowledged by the parties, and intending to be legally bound, the parties agree as follows: 
  

	1.	 Payment. 

  

	 	a.	 Within five (5) business days following the date hereof, Allergan shall pay ten million dollars
($10,000,000) less any applicable withholding taxes (the “Initial Purchase Price”) in cash by wire transfer of immediately available funds to the account designated by Histogen prior to the date hereof and set forth on Exhibit
A attached hereto (the “Account”). 

  

	 	b.	 If Net Sales of Products under the License Agreement in any calendar year from the calendar year ending
December 31, 2017 through and including the calendar year ending December 31, 2027 exceed sixty million dollars ($60,000,000) (the “Net Sales Milestone”), then, no later than March 1 of the year following the year in which
the Net Sales Milestone was achieved, Allergan shall pay to Histogen a one-time milestone payment equal to five million, five hundred thousand dollars ($5,500,000) less any applicable withholding taxes (the
“Milestone Payment”) in cash by wire transfer of immediately available funds to the Account or an account designated by Histogen at least five (5) business days prior to the date of such payment. 

 

	2.	 Article 1. Article 1 of the License Agreement shall be amended as follows: 

 

	 	a.	 Section 1.30 of the License Agreement shall be deleted in its entirety and replaced with the following:

 1.30 Reserved 
  

	3.	 Article 2. Article 2 of the License Agreement shall be amended as follows: 

 

	 	a.	 Section 2.1.1 shall be amended and restated as follows: 

2.1.1 License Grant 
 Histogen,
on behalf of itself and its Affiliates, hereby grants to Allergan an exclusive (even as to Histogen and its Affiliates), royalty-free, fully paid-up, perpetual, irrevocable,
non-terminable, transferable license, with the right to grant sublicenses, under the Licensed Intellectual Property, solely in the Field of Use and within the Territory and solely to make, have made, use,
import and export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and 
 otherwise commercially exploit the
Products throughout the Territory. Histogen, on behalf of itself and its Affiliates, hereby grants to Allergan a non-exclusive, royalty free, fully paid up, perpetual, irrevocable, non-terminable, transferrable license, with the right to grant sublicenses, under the CCM Technical Information, solely in the Field of Use and within the Territory and solely to make, have made, use, import and
export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and otherwise commercially exploit the Products throughout the Territory. For clarity, if any products in the SkinMedica product line, or any other product line
developed by Allergan and/or its Affiliates include CCM as an ingredient, then such products shall constitute “Products.” 

  
 -2- 

	 	b.	 Section 2.2 shall be amended and restated as follows: 

2.2 Sublicensing 

Allergan shall have the unqualified right to sublicense any of the rights granted in Section 2.1 to one or more of its Affiliates and/or
Third Parties. 
  

	4.	 Article 4. Article 4 of the License Agreement shall be amended as follows. 

 

	 	a.	 Section 4.2.1 of the License Agreement shall be deleted in its entirety and replaced with the following:

 4.2.1 Reserved 
  

	 	b.	 Section 4.2.2 of the License Agreement shall be amended to remove the following words at the beginning
thereof: “Subject to this Section 4.2.” 

  

	 	c.	 Section 4.2.3 of the License Agreement shall be shall be deleted in its entirety and replaced with the
following: 

 4.2.3 Reserved 
  

	5.	 Article 6. Article 6 of the License Agreement shall be amended as follows. 

 

	 	a.	 Section 6.2 of the License Agreement shall be deleted in its entirety and replaced with the following:

 6.2 Reserved 
  

	 	b.	 Section 6.3 of the License Agreement shall be as follows: 

 

	 	i.	 Delete the third sentence thereof. 

 

	 	ii.	 Amend and restate the fifth sentence to read as follows: 

If Allergan is the party that obtains such a license, Histogen shall reimburse Allergan for the reasonable and documented amounts paid to the
applicable Third Party licensor. 
  

	6.	 Article 7. Article 7 of the License Agreement shall be amended as follows. 

 

	 	a.	 Section 7.1 of the License Agreement shall be deleted in its entirety and replaced with the following:

 7.1 Records and Audits 

  
 -3- 

 Allergan shall keep such books of account containing complete and accurate particulars as
may be reasonably necessary for the purpose of showing Net Sales of Products during the most recent three (3) year period; provided, that Allergan shall have no obligation to keep such books of account for any time period following the calendar
year ending December 31, 2027. Until the earlier of (a) three (3) years following the end of the Term and (b) December 31, 2030, Allergan shall make such books of account available (no more than one inspection per year (which may
comprise more than one day for inspection) upon reasonable prior written notice to Allergan) for inspection by Histogen’s designated accounting firm reasonably acceptable to Allergan, for the purpose of verifying whether the Net Sales Milestone
(as defined in Amendment No. 2 to this Agreement) was achieved; provided, however, that if an inspection shows for any audited period that the Net Sales Milestone was achieved and the Milestone Payment (as defined in Amendment No. 2 to
this Agreement) was not paid, then Allergan shall reimburse Histogen for the reasonable, documented cost of the inspection at the time Allergan pays the Milestone Payment to Histogen. In the event that any inspection reveals that the Net Sales
Milestone was achieved and the Milestone Payment not paid, Allergan shall pay the Milestone Payment to Histogen within ten (10) business days after the inspection is completed. Histogen shall cause the accounting firm to retain all information
subject to review under this Section 7.1 in confidence. In addition, Allergan shall have the right to require that such accounting firm, prior to conducting such inspection, enter into a reasonable
non-disclosure agreement with Allergan regarding such information. Histogen will cause the accounting firm to make all results of any such inspection available to Allergan. The accounting firm shall disclose
to Histogen only whether Allergan’s Net Sales Report was correct, the amount of any discrepancy and whether or not the Net Sales Milestone was achieved. No other information shall be shared with Histogen. Histogen shall treat all such
information as Allergan’s Confidential Information (as defined in Section 14.2). 
  

	 	b.	 Section 7.2 of the License Agreement shall be deleted in its entirety and replaced with the following:

 7.2 Net Sales Reports 

Within forty-five (45) days after the end of each calendar year from the year ended December 31, 2017 through and including the
earlier of (i) the year ending December 31, 2027 and (ii) the year in which the Net Sales Milestone is achieved and for which the Milestone Payment is paid, Allergan shall deliver to Histogen a complete and accurate report (the
“Net Sales Report”) setting forth: 
 (a) gross amounts invoiced for each Product by Allergan and its Affiliates and any
Sublicensees for such calendar year; and 
 (b) the calculation of Net Sales of Products for such calendar year. 

 

	7.	 Article 8. Article 8 of the License Agreement shall be amended as follows. 

  
 -4- 

	 	a.	 Section 8.1.2 shall be amended to the delete the following words at the end thereof:

 and Allergan shall have no further obligation to pay royalties on Products Covered by such Patent Right 

 

	8.	 Article 10. Article 10 of the License Agreement shall be amended as follows: 

 

	 	a.	 Section 10.1 shall be amended to delete the following words each time they appear in such section:

 Section 10.2, Section 10.3, Section 10.4 or 

 

	 	b.	 Section 10.2 shall be deleted in its entirety and replaced with the following: 

10.2 Reserved 
  

	 	c.	 Section 10.3 shall be deleted in its entirety and replaced with the following: 

10.3 Reserved 
  

	 	d.	 Section 10.4 shall be deleted in its entirety and replaced with the following: 

10.4 Reserved 
  

	 	e.	 Section 10.5 shall be deleted by deleting the word “year’s” and replacing such word with
the words “business day’s.” 

  

	9.	 Article 15. Article 15 of the License Agreement shall be amended as follows: 

 

	 	a.	 Section 15.2 of the License Agreement shall be amended and restated as follows: 

This Agreement and the rights and duties appertaining hereto may not be assigned or otherwise transferred by Histogen without first obtaining
the written consent of Allergan, which consent shall not be unreasonably withheld, conditioned or delayed. However, if Histogen is acquired by a Third Party, (whether through an acquisition of equity or merger), or if all or substantially all of
Histogen’s assets are acquired by a Third Party, then Histogen may assign its rights and obligations to said acquiring Third Party without the consent of Allergan. So long as the assignee is capable of paying amounts that may become payable,
Allergan may assign this Agreement and its rights, duties and obligations hereunder to any Affiliate of Allergan or any Third Party without the consent of Histogen. 
  

	10.	 Representations and Warranties. The representations and warranties set forth in Article 11 of the License
Agreement are incorporated by reference herein and each of the parties hereto makes the representations and warranties made by it in Article 11 of the License Agreement as of the date hereof, except that each reference to the License Agreement
therein shall be deemed to be a reference to this Amendment. 

  
 -5- 

	11.	 Effects on Agreement. Contingent upon Histogen’s receipt of the Initial Purchase Price:

  

	 	a.	 This Amendment and all modifications to the License Agreement set forth herein shall be effective from
October 1, 2017 (the “Amendment Effective Date”). From and as of the Amendment Effective Date, each reference to the License Agreement, shall be deemed to be a reference to the License Agreement as amended by this Amendment.

  

	 	b.	 Subject to the foregoing amendments, all terms and conditions of the License Agreement shall remain in full
force and effect to the extent they are so on the Amendment Effective Date; provided, however, that to the extent the License Agreement contains provisions that are affected by the terms of this Amendment, the parties hereto acknowledge and agree
that such provisions will be interpreted consistent with the changes made pursuant to this Amendment. 

  

	 	c.	 With respect to the relative obligations of the parties to the License Agreement for all periods prior to and
including the Amendment Effective Date, the provisions in effect immediately prior to giving effect to this Amendment shall govern. 

  

	 	d.	 Nothing in this Amendment shall relieve any of Histogen or Allergan of any liability for any breach of the
License Agreement (as it existed prior to giving effect to this Amendment) prior to the date hereof. 

  

	12.	 No Awareness of Breach. Each of Histogen and Allergan represents and warrants that it is not aware of any
breach of the License Agreement by the other party prior to the date hereof. 

  

	13.	 General Provisions. 

  

	 	a.	 From time to time, at the reasonable request of either party, the other party shall execute and deliver such
documents and take such other action as the requesting party may reasonable request to consummate the transactions contemplated hereby. 

  

	 	b.	 This Amendment, and any disputes arising directly or indirectly from this Amendment, shall be governed by and
construed and enforced in accordance with the laws of the state of California, without regard to its conflict-of-laws rules. The parties agree that any claims arising
under this Amendment shall be exclusively venued in the state and federal courts located in San Diego County, California. Each party hereby irrevocably submits to the exclusive jurisdiction of such courts for any such claims, and waives any
objections to the laying of venue in such courts. Unless expressly provided otherwise, each right and remedy in this Amendment is in addition to any other right or remedy, at law or in equity, and the exercise of one right or remedy will not be
deemed a waiver of any other right or remedy. 

  

	 	c.	 This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. This Amendment may be signed and delivered to the other party by facsimile or PDF attachment signature; such transmission will be deemed a valid signature. 

[Signature Page Follows] 

  
 -6- 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment in duplicate
originals by their proper officers as of the date and year first above written. 
  

									
	ALLERGAN SALES, LLC	 		 	HISTOGEN, INC.
					
	By:	 	 /s/ Kira Schwartz
	 		 	By:	 	 /s/ Stephen Hill

		 	Name: Kira Schwartz	 		 		 	Name: Stephen Hill
		 	Title: Secretary	 		 		 	Title: Vice President & Controller

  
 -7-EX-10.64

 Exhibit 10.64 

AMENDMENT NO. 3 TO 

AMENDED AND RESTATED LICENSE AGREEMENT 

AMENDMENT NO. 2 TO 

AMENDED AND RESTATED SUPPLY AGREEMENT 

This Amendment No. 3 to the Amended and Restated License Agreement and Amendment No. 2 to the Amended and Restated Supply Agreement
(this “Amendment”) is made as of March 22, 2019 by and between Histogen, Inc. (“Histogen”) and Allergan Sales, LLC (“Allergan”). 

WHEREAS, Suneva Medical, Inc. (“Suneva”) and Histogen previously entered into that certain License Agreement dated as
of February 3, 2012 (the “Original License Agreement”) and that certain Supply Agreement dated as of February 3, 2012 (the “Original Supply Agreement” and, together with the “Original License
Agreement,” the “Original Agreements”); 
 WHEREAS, on December 16, 2013, Suneva and Histogen entered into
the Amended and Restated License Agreement (as modified by Amendment No. 1 and Amendment No. 2 (each, as defined below), the “License Agreement” capitalized terms used herein and not otherwise defined shall have the
meanings ascribed to such terms in the License Agreement) and the Amended and Restated Supply Agreement (as modified by Amendment No. 1, the “Supply Agreement”), amending and restating the Original Agreements in their entirety,
maintaining except as otherwise expressly stated therein, the original February 3, 2012 effective date; 
 WHEREAS, on
July 7, 2017, Allergan and Suneva entered into an Asset Purchase Agreement (the “APA”), pursuant to which, among other things, Suneva agreed to sell Suneva’s ReGenica product line to Allergan, subject to the terms and
conditions set forth in the APA (the “Regenica Transaction”); 
 WHEREAS, on July 11, 2017, Suneva, Histogen
and Allergan entered into that certain letter agreement (“Amendment No. 1”), pursuant to which, among other things, (i) Histogen consented to the assignment by Suneva of the License Agreement and the Supply
Agreement to Allergan, (ii) Allergan accepted the assignment of all of Suneva’s rights and obligations under the License Agreement and the Supply Agreement from and after the closing of the Regenica Transaction (the
“Closing”), (iii) Allergan, Suneva and Histogen agreed that with effect from the Closing, Allergan would replace Suneva as a party to the License Agreement and the Supply Agreement, entitled to all rights granted to Suneva pursuant
to the License Agreement and the Supply Agreement and subject to all obligations of Suneva pursuant to the License Agreement and the Supply Agreement and that all references to “Suneva” in the License Agreement should be deemed references
to “Allergan,” and (iv) Allergan, Suneva and Histogen agreed to certain other modifications to the License Agreement and the Supply Agreement to become effective subject to the Closing; 

WHEREAS, the Closing occurred on July 24, 2017; 

WHEREAS, on October 25, 2017, Allergan and Histogen entered into Amendment No. 2 to the License Agreement (“Amendment
No. 2”), pursuant to which, among other things, for consideration, the parties modified the licenses granted pursuant to the License Agreement to be royalty-free, fully paid-up,
perpetual, irrevocable, non-terminable and transferable, with the right to grant sublicenses; and 

  
 -1- 

 WHEREAS, Allergan and Histogen desire to further amend the License Agreement and the Supply
Agreement to, among other things, modify the Field of Use therein. 
 NOW, THEREFORE, for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged by the parties, and intending to be legally bound, the parties agree as follows: 
  

	1.	 Payment. 

  

	 	a.	 Within five (5) business days following the date hereof, Allergan shall pay seven million, five hundred
thousand dollars ($7,500,000) less any applicable withholding taxes (the “Consideration”) in cash by wire transfer of immediately available funds to the account designated by Histogen prior to the date hereof and set forth on
Exhibit A attached hereto. 

  

	2.	 License Agreement Article 1. Article 1 of the License Agreement shall be amended as follows:

  

	 	a.	 The following is added to the License Agreement as a new Section 1.3(a) immediately following
Section 1.3: 

 “1.3(a) “Allergan Product” means a Product sold under a brand or
Trademark owned by or exclusively licensed to Allergan or any of its Affiliates.” 
  

	 	b.	 The following is added to the License Agreement as a new Section 1.8(a) immediately following
Section 1.8: 

 “1.8(a) “Exclusive Field of Use” means
Products used to address any symptom or condition related to topical cosmetic applications, including without limitation, for enhancement of use of, or recovery from, microneedling, cosmetic wound healing,
non-implantable device coating and the signs, symptoms and appearance of aging skin, (i) dispensed, sold, distributed, supplied, marketed, commercialized, commercially exploited, made available or
otherwise provided, directly or indirectly, by a physician from the physician’s office, clinic, hospital, medical spa or website associated with a medical license number or (ii) dispensed, sold, distributed, supplied, marketed,
commercialized, commercially exploited, made available or otherwise provided to customers (including, without limitation, end users) through the Amazon.com Professional Beauty channel or any website or digital platform owned or licensed by Allergan
or any of its Affiliates or otherwise branded in the name of Allergan or any of its Affiliates. For clarity, Exclusive Field of Use does not include hair growth/care, non-cosmetic wound healing, implantable
device coatings, orthopedics, oncology, cuticle/nail growth/care, muscle growth/regeneration/care, or dermal fillers.” 

  
 -2- 

	 	c.	 Section 1.10 of the License Agreement shall be deleted in its entirety and replaced with the following:

 “1.10 “Field of Use” means the Exclusive Field of Use
and the Non-Exclusive Field of Use, collectively.” 
  

	 	d.	 The following is added to the License Agreement as a new Section 1.21(a) immediately following
Section 1.21: 

 “1.21(a) “Luxury Platform” means any
website or digital platform owned by an entity owning and operating any of the following brick-and-mortar retailers and through which the applicable retailer markets and
sells it goods to consumers: (a) Barneys, Bloomingdales, Fred Segal, Holt Renfrew, Bergdorf Goodman, Neiman Marcus, Saks Fifth Avenue and similar renowned luxury retailers selling luxury goods at a similar price point to the foregoing and
(b) Sephora, Ulta Beauty and similar beauty specialist retailers.” 
  

	 	e.	 The following is added to the License Agreement as a new Section 1.22(a) immediately following
Section 1.22: 

 “1.22(a)
“Non-Exclusive Field of Use” means Products used to address any symptom or condition related to topical cosmetic applications, including without limitation, for enhancement
of use of, or recovery from, microneedling, cosmetic wound healing, non-implantable device coating and the signs, symptoms and appearance of aging skin, dispensed, sold, distributed, supplied, marketed,
commercialized, commercially exploited, made available or otherwise provided to customers (including, without limitation, end users) (i) through any website or other digital platform, including Amazon.com, that is not a Luxury Platform and is
not described in the definition of “Exclusive Field of Use” or (ii) at or by any brick-and-mortar non-medical spa,
salon or wellness center, excluding any brick-and-mortar business operated by any retailer included within the definition of “Luxury Platform.” For clarity, Non-Exclusive Field of Use does not include hair growth/care, non-cosmetic wound healing, implantable device coatings, orthopedics, oncology, cuticle/nail growth/care, muscle
growth/regeneration/care, or dermal fillers.” 
  

	 	f.	 Section 1.29 of the License Agreement is amended and restated as follows: 

“1.29 “Regulatory Filings and Approvals” means any and all permits, licenses, approvals, designations and
authorizations (a) required by any Regulatory Authority as a prerequisite to the development, manufacturing, marketing, selling and/or use in the Territory of (i) a Product in the Exclusive Field of Use or (ii) an Allergan Product in
the Non-Exclusive Field of Use, or (b) otherwise issued by any Regulatory Authority in the Territory with respect to any (i) Product in the Exclusive Field of Use or (ii) Allergan Product in the
Non-Exclusive Field of Use, in each case, as well as any applications for any of the foregoing filed with any Regulatory Authority.” 

  
 -3- 

	3.	 License Agreement Article 2. Article 2 of the License Agreement shall be amended as follows:

  

	 	a.	 Section 2.1.1 of the License Agreement shall be amended and restated as follows: 

“2.1.1 License Grant 

Histogen, on behalf of itself and its Affiliates, hereby grants to Allergan an exclusive (even as to Histogen and its Affiliates),
royalty-free, fully paid-up, perpetual, irrevocable, non-terminable, transferable license, with the right to grant sublicenses, under the Licensed Intellectual Property,
solely in the Exclusive Field of Use and within the Territory and solely to make, have made, use, import and export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and otherwise commercially exploit the Products
throughout the Territory. Histogen, on behalf of itself and its Affiliates, hereby grants to Allergan a non-exclusive, royalty-free, fully paid-up, perpetual,
irrevocable, non-terminable, transferable license, with the right to grant sublicenses, under the Licensed Intellectual Property, solely in the Non-Exclusive Field of
Use and within the Territory and solely to make, have made, use, import and export, develop, register, warehouse, distribute, market, promote, offer to sell, sell and otherwise commercially exploit the Products throughout the Territory. Histogen, on
behalf of itself and its Affiliates, hereby grants to Allergan a non-exclusive, royalty free, fully paid up, perpetual, irrevocable, non-terminable, transferrable
license, with the right to grant sublicenses, under the CCM Technical Information, solely in the Field of Use and within the Territory and solely to make, have made, use, import and export, develop, register, warehouse, distribute, market, promote,
offer to sell, sell and otherwise commercially exploit the Products throughout the Territory. For clarity, if any products in the SkinMedica product line, or any other product line developed by Allergan and/or its Affiliates include CCM as an
ingredient, then such products shall constitute “Products.” 
  

	4.	 License Agreement Article 3. Article 3 of the License Agreement shall be amended as follows:

  

	 	a.	 Section 3.1 of the License Agreement shall be amended and restated as follows: 

“3.1 Ownership and Maintenance of Regulatory Filings and Approvals 

As between the parties, Allergan shall solely own any Regulatory Filings and Approvals throughout the Territory that are either:
(i) pending or in effect as of the Effective Date or (ii) made by or on behalf of Allergan or any of its Affiliates, or are obtained by or on behalf of Allergan or any of its Affiliates, following the Effective Date. Allergan, in its sole
discretion, will be responsible for the filing and maintenance of any Regulatory Filings and Approvals deemed necessary for the marketing of the Products. Histogen shall promptly notify Allergan in writing of any correspondence received from any
Regulatory Authority relating to any Product with respect to the manufacture of Product, Field of Use and the Territory, or Regulatory Filings and Approvals relating to any Product with respect to the Field of Use and the Territory, and shall
provide Allergan with copies of any such 

  
 -4- 

 
correspondence. Histogen will provide Allergan and its Affiliates with reasonable assistance, at no charge to Allergan, with respect to Regulatory Filings and Approvals throughout the Territory
that are either: (i) pending or in effect as of the Effective Date or (ii) made by or on behalf of Allergan or any of its Affiliates, or are obtained by or on behalf of Allergan or any of its Affiliates, following the Effective Date.”

  

	5.	 License Agreement Article 4. Article 4 of the License Agreement shall be amended as follows:

  

	 	a.	 Section 4.2.2 of the License Agreement shall be amended and restated as follows: 

“Subject to this Section 4.2, Allergan shall have sole discretion in the Territory over all regulatory,
marketing, pricing, promotion, strategy, reimbursement, branding, distribution and sales issues relating to (a) any Product in the Exclusive Field of Use and (b) any Allergan Product in the
Non-Exclusive Field of Use.” 
  

	 	b.	 Section 4.4 of the License Agreement shall be amended to insert the word “Exclusive” immediately
prior to the words “Field of Use” therein. 

  

	 	c.	 Section 4.6 of the License Agreement shall be amended to insert the word “Exclusive” immediately
prior to the words “Field of Use” therein. 

  

	6.	 Supply Agreement Article 2. Article 2 of the Supply Agreement shall be amended as follows:

  

	 	a.	 Section 2.1(b) of the Supply Agreement shall be amended to insert the word “Exclusive”
immediately prior to the words “Field of Use” therein. 

  

	7.	 Representations and Warranties. The representations and warranties set forth in Article 11 of the
License Agreement and Article 7 of the Supply Agreement are incorporated by reference herein and each of the parties hereto makes the representations and warranties made by it in Article 11 of the License Agreement and Article 7 of the Supply
Agreement as of the date hereof, except that each reference to the License Agreement and the Supply Agreement therein shall be deemed to be a reference to this Amendment. 

 

	8.	 Effects on Agreement. Contingent upon Histogen’s receipt of the Consideration:

  

	 	a.	 This Amendment and all modifications to the License Agreement and the Supply Agreement set forth herein shall
be effective from March 1, 2019 (the “Amendment Effective Date”). From and as of the Amendment Effective Date, (i) each reference to the License Agreement, shall be deemed to be a reference to the License Agreement as
amended by this Amendment and (ii) each reference to the Supply Agreement, shall be deemed to be a reference to the Supply Agreement as amended by this Amendment. 

 

	 	b.	 Subject to the foregoing amendments, all terms and conditions of the License Agreement and the Supply Agreement
shall remain in full force and effect to the extent they are so on the Amendment Effective Date; provided, however, that to the extent the License Agreement or the Supply Agreement contains provisions that are affected by the terms of
this Amendment, the parties hereto acknowledge and agree that such provisions will be interpreted consistent with the changes made pursuant to this Amendment. 

  
 -5- 

	 	c.	 With respect to the relative obligations of the parties to the License Agreement and the Supply Agreement for
all periods prior to and including the Amendment Effective Date, the provisions in effect immediately prior to giving effect to this Amendment shall govern. 

  

	 	d.	 Nothing in this Amendment shall relieve any of Histogen or Allergan of any liability for any breach of the
License Agreement or Supply Agreement (as they existed prior to giving effect to this Amendment) prior to the date hereof. 

  

	9.	 No Awareness of Breach. Each of Histogen and Allergan represents and warrants that it is not aware of
any breach of the License Agreement or the Supply Agreement by the other party prior to the date hereof. 

  

	10.	 General Provisions. 

 

	 	a.	 From time to time, at the reasonable request of either party, the other party shall execute and deliver such
documents and take such other action as the requesting party may reasonable request to consummate the transactions contemplated hereby. 

  

	 	b.	 This Amendment, and any disputes arising directly or indirectly from this Amendment, shall be governed by and
construed and enforced in accordance with the laws of the state of California, without regard to its conflict-of-laws rules. The parties agree that any claims arising
under this Amendment shall be exclusively venued in the state and federal courts located in San Diego County, California. Each party hereby irrevocably submits to the exclusive jurisdiction of such courts for any such claims, and waives any
objections to the laying of venue in such courts. Unless expressly provided otherwise, each right and remedy in this Amendment is in addition to any other right or remedy, at law or in equity, and the exercise of one right or remedy will not be
deemed a waiver of any other right or remedy. 

  

	 	c.	 This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all
of which together shall constitute one and the same instrument. This Amendment may be signed and delivered to the other party by facsimile or PDF attachment signature; such transmission will be deemed a valid signature. 

[Signature Page Follows] 

  
 -6- 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment in duplicate
originals by their proper officers as of the date and year first above written. 
  

									
	ALLERGAN SALES, LLC	 		 	HISTOGEN, INC.
					
	By:	 	 /s/ Sigurd Kirk
	 	            	 	By:	 	 /s/ Richard W. Pascoe

		 	Name: Sigurd Kirk	 		 		 	Name: Richard W. Pascoe
		 	Title: Vice President	 		 		 	Title: Chairman and CEO

  
 -7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]